A Phase 2 Trial of Daily Alternating Thalidomide and Lenalidomide Plus Rituximab (ThRiL) for Patients with Previously Treated Waldenstrom Macroglobulinemia
Update: this study is closed to enrollment.
The Weill Cornell Lymphoma Program is now enrolling patients in a newly opened, investigator-initiated clinical trial for people with previously treated Waldenstrom Macroglobulinemia. The principal investigator is Peter Martin, MD.
For more information about the study, please call Amelyn Rodriguez, RN at (212) 746-1362 or email Amelyn at amr2017@med.cornell.edu.
Key eligibility
- Previously treated for Waldenstrom Macroglobulinemia
- Not currently treated with other anti-cancer agents or treatments
- No prior treatment with thalidomide or lenalidomide
- Detailed eligibility reviewed when you contact the study team
Study Details
The study is evaluating the efficacy and safety of daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in people with previously treated Waldenstrom Macroglobulunemia (WM).
Thalidomide and lenalidomide are drugs that modulate the immune system and have been shown to bring about responses in patients with WM. However, their use has been limited due to side effects. Alternating doses of thalidomide and lenalidomide may alleviate the side effects while preserving the effectiveness of the therapies.
Treatment Plan
- Thalidomide every ODD day of a 28 day cycle
- Lenalidomide every EVEN day of a 28 day cycle
- Rituximab on Days 1, 8, 15 and 22 and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycles 7, 13, 19, etc)
Study participants may continue to receive thalidomide and lenalidomide until their disease worsens.
New Developments in Lymphoma 